despit
recent
increas
develop
antivir
antibiot
antimicrobi
resist
lack
broadspectrum
virustarget
drug
still
import
issu
addit
altern
approach
treat
infecti
diseas
urgent
need
hostdirect
therapi
hdt
emerg
approach
field
antiinfect
strategi
behind
hdt
interfer
host
cell
factor
requir
pathogen
replic
persist
enhanc
protect
immun
respons
pathogen
reduc
exacerb
inflamm
balanc
immun
reactiv
site
patholog
although
hdt
encompass
interferon
well
establish
treatment
chronic
viral
hepat
novel
strategi
aim
function
cure
persist
viral
infect
develop
broadspectrum
antivir
emerg
virus
seem
crucial
chronic
bacteri
infect
tuberculosi
hdt
strategi
aim
enhanc
antimicrobi
activ
phagocyt
curtail
inflamm
interfer
solubl
factor
eicosanoid
cytokin
cellular
factor
costimulatori
molecul
review
describ
current
progress
develop
hdt
viral
bacteri
infect
includ
sepsi
challeng
bring
new
approach
clinic
natur
review
drug
discoveri
volum
januari
review
c
l
l
n
p
u
b
l
h
e
r
l
e
p
r
f
p
r
n
g
e
r
n
u
r
e
l
l
r
g
h
r
e
e
r
v
e
infecti
diseas
caus
bacteri
viral
pathogen
remain
major
global
health
threat
antibiot
contribut
profound
reduct
diseas
incid
caus
bacteri
pathogen
increasingli
face
antimicrobi
resist
amr
antibiot
develop
new
antibacteri
lag
behind
emerg
resist
estim
death
caus
pathogen
antimicrobi
resist
persist
viral
infect
rare
cure
major
epidem
pandem
caus
ebola
viru
zika
viru
underscor
need
broadli
activ
antivir
moreov
avail
antivir
often
limit
rapid
emerg
drug
resist
approxim
new
antivir
drug
approv
past
year
approv
past
year
mostli
select
treatment
infect
hepat
c
viru
hcv
hiv
clear
rise
r
antivir
drug
contrast
antibiot
activ
spectrum
mostli
limit
distinct
viru
group
mani
virus
particularli
highli
preval
develop
countri
includ
hepat
flavivirus
drug
avail
moreov
constant
emerg
infect
new
viru
speci
increas
incid
outbreak
viral
diseas
pandem
potenti
emphas
need
broadspectrum
antivir
drug
undoubtedli
r
canon
antimicrobi
directli
target
pathogen
must
continu
addit
approach
also
urgent
need
one
complement
strategi
hostdirect
therapi
hdt
biolog
small
molecul
hdt
interfer
host
mechan
requir
pathogen
product
replic
persist
enhanc
immun
respons
stimul
mechan
involv
host
defenc
pathogen
target
pathway
perturb
pathogen
contribut
hyperinflamm
modul
host
factor
lead
dysbalanc
respons
site
patholog
case
target
hyperinflamm
dysbalanc
respons
treatment
symptomat
rather
causal
reduc
exacerb
tissu
damag
infecti
diseas
confin
microbi
nich
accordingli
hdt
infecti
diseas
share
similar
convent
therapi
noncommunic
diseas
kaufmann
mpiibberlinmpg
de
ancadorhoi
fli
de
richardshotchkiss
wustledu
ralfbartenschlag
med
uniheidelbergd
inde
sever
hdt
approach
reli
repurpos
licens
drug
diseas
cancer
metabol
cardiovascular
diseas
howev
area
infecti
diseas
antiinfect
directli
target
pathogen
gener
consid
treatment
option
therefor
concept
hdt
infecti
diseas
although
novel
strictest
sens
provid
untap
opportun
urgent
need
face
increas
amr
hdtbase
approach
less
prone
therapi
resist
antiinfect
directli
target
pathogen
resist
would
requir
pathogen
use
altern
host
factor
replic
becom
less
depend
target
host
factor
evad
activ
host
defenc
mechan
princip
host
factor
evolutionarili
conserv
therefor
success
evas
requir
consider
mutat
chang
pathogen
nevertheless
hdt
approach
consid
standalon
therapi
combin
canon
antiinfect
review
compar
differ
hdt
approach
viral
bacteri
infect
describ
progress
made
develop
focus
mostli
tuberculosi
tb
box
sepsi
bacteri
infect
chronic
viral
hepat
aid
viral
infect
tabl
also
provid
deeper
insight
gener
principl
underli
differ
diseas
note
common
differ
hdt
distinct
infect
owe
space
limit
recent
publish
review
topic
prophylact
therapeut
vaccin
cover
exampl
mention
supplementari
inform
tabl
interf
host
cell
mechan
virus
bacteria
intracellular
parasit
requir
host
cell
replic
persist
one
hand
host
cell
provid
among
mechan
synthet
machineri
energi
sourc
hand
host
cell
intrins
defenc
mechan
trigger
infect
therefor
virus
bacteria
must
possess
strategi
block
defenc
take
advantag
increas
knowledg
pathogenhost
cell
interact
novel
strategi
hdt
current
pursu
either
block
host
cell
factor
pathway
essenti
pathogen
surviv
activ
reinstal
pathogenantagon
mechan
thu
render
host
cell
nonpermiss
viral
infect
begin
attach
virion
host
cell
process
requir
specif
interact
protein
expos
surfac
viru
particl
one
sever
receptor
plasma
membran
host
cell
fig
interact
trigger
entri
viru
particl
cell
dissoci
nucleocapsid
ultim
releas
viral
genom
use
revers
transcript
integr
case
hiv
rna
synthesi
exampl
hepat
b
viru
hbv
directli
protein
product
hcv
fig
viral
protein
togeth
host
cell
factor
catalys
amplif
viral
genom
packag
progeni
virion
releas
cell
initi
new
round
infect
virus
requir
host
cell
factor
nearli
everi
step
life
cycl
requir
host
depend
factor
hdf
potenti
drug
target
ideal
moder
reduct
hdf
abund
avail
would
alreadi
substanti
impair
viru
product
hdf
would
nonessenti
host
cell
surviv
would
reduc
likelihood
cytotox
accordingli
inhibitor
target
earli
stage
viral
replic
block
bind
viru
particl
host
cell
receptor
emerg
promis
approach
supplementari
inform
tabl
regard
entri
inhibitor
past
two
decad
progress
made
treatment
infect
hiv
type
entri
viru
requir
interact
primari
receptor
one
two
chemokin
receptor
act
coreceptor
cxcchemokin
receptor
ccchemokin
receptor
fig
wherea
express
cell
promot
entri
celltrop
express
macro
phage
popul
cell
promot
entri
macrophagetrop
strain
intriguingli
individu
certain
mutat
resist
infect
strain
predomin
earli
stage
infect
wherea
strain
emerg
later
stage
infect
thu
qualifi
attract
target
hdt
antagonist
develop
lock
receptor
nonpermiss
conform
therebi
dampen
coreceptor
function
concept
origin
establish
vitro
translat
clinic
use
maraviroc
selzentrycelsentri
pfizer
approv
firstinclass
inhibitor
expect
hdt
resist
maraviroc
low
given
import
hiv
infect
maraviroc
becom
compon
therapi
apart
virolog
benefit
maraviroc
also
found
increas
number
cell
patient
suggest
addit
result
clinic
trial
conduct
demonstr
excel
toler
even
high
dose
myrcludex
b
moreov
phase
ibiia
clinic
trial
myrcludex
b
monotherapi
patient
chronic
hbvhdv
coinfect
reveal
strong
reduct
hdv
rna
serum
level
normal
liver
enzym
marker
liver
cell
damag
also
synergist
antivir
effect
hdv
hbv
level
patient
treat
combin
myrcludex
b
polyethylen
glycolconjug
pegyl
interferon
myrcludex
b
receiv
orphan
drug
statu
european
medicin
agenc
ema
us
food
drug
administr
fda
clinic
trial
ongo
myrcludex
b
maraviroc
illustr
entri
inhibit
promis
target
hdt
support
broad
applic
hdt
strategi
recent
identif
entri
molecul
ebola
viru
lassa
viru
picornavirus
provid
ideal
start
point
develop
hdt
threaten
pathogen
target
hdf
requir
hcv
replic
apart
target
entri
receptor
hdf
requir
viral
replic
equal
attract
drug
target
one
exampl
host
cell
chaperon
cyclophilin
cypa
use
repliconbas
assay
found
immuno
suppress
drug
cyclosporin
csa
potent
inhibit
hcv
replic
bind
therebi
sequest
cypa
subsequ
studi
identifi
cypa
primari
hdf
promot
hcv
replic
accord
tuberculosi
tb
caus
bacterium
mycobacterium
tuberculosi
mtb
remain
deadliest
global
infecti
diseas
million
death
caus
singl
pathogen
modifi
host
defenc
mechan
mtb
persist
surviv
rest
macrophag
macrophag
activ
cell
cytokin
improv
bacteri
control
activ
remain
incomplet
activ
tb
emerg
either
progress
primari
diseas
consequ
immun
suppress
long
stage
pathogen
persist
balanc
bacteri
persist
host
defenc
tip
favour
pathogen
mtb
modul
chemokin
cytokin
releas
advantag
trigger
recruit
addit
mtbpermiss
cell
site
infect
releas
alarmin
protein
upon
lysi
infect
macrophag
recruit
immun
cell
within
lung
resid
recruit
phagocyt
cluster
give
rise
granuloma
tissu
hallmark
tb
granuloma
complex
highli
dynam
cellular
structur
compos
macrophag
variou
activ
stage
dendrit
cell
dc
neutrophil
natur
killer
nk
cell
b
lymphocyt
divers
cellular
composit
local
remodel
event
necrosi
fibrosi
miner
caseat
drive
granuloma
heterogen
highlight
presenc
distinct
microenviron
singl
lesion
granuloma
follow
uniqu
trajectori
result
dynam
interact
bacteri
factor
host
immun
moreov
continuum
distinct
lesion
present
given
host
solid
granuloma
domin
healthi
individu
latent
infect
caseou
granuloma
predomin
patient
activ
tb
granuloma
harbour
mtb
within
macrophag
region
acellular
necrosi
variou
metabol
lipid
speci
anatom
abnorm
blood
vessel
factor
restrict
penetr
antimicrobi
drug
granuloma
caviti
origin
caseat
granuloma
enabl
unrestrict
mtb
replic
pellicl
caviti
wall
sourc
bacillari
expector
transmiss
multidrugresist
mdr
tb
extens
drugresist
xdr
tb
contribut
tbrelat
death
occurr
drugresist
tb
attribut
poor
patient
complianc
chemotherapi
gener
compris
four
drug
isoniazid
rifampin
ethambutol
pyrazinamid
last
month
addit
poor
complianc
genet
divers
clonal
mtb
within
patient
well
reduc
drug
penetr
lesion
lead
monotherapi
site
bacteri
resid
despit
treatment
sever
drug
contribut
emerg
antimicrobi
resist
amr
tb
equal
alarm
fast
acquisit
resist
newli
approv
drug
mdr
tb
delamanid
bedaquilin
therefor
develop
amr
along
limit
treatment
option
mdr
tb
xdr
tb
call
hostdirect
therapi
primarili
adjunct
canon
chemotherapi
type
extent
mutat
requir
pathogen
escap
suppress
effect
impos
specif
drug
directact
antivir
drug
daa
compound
bind
affect
virusencod
factor
often
protein
exampl
proteas
polymeras
inhibitor
cypa
like
requir
proper
assembl
activ
hcv
replicas
complex
sequestr
render
replicas
inact
howev
cypacsa
complex
inhibit
protein
phosphatas
calcineurin
requir
cell
activ
thu
caus
immuno
suppress
effect
therefor
nonimmunosuppress
cyp
antagonist
mostli
deriv
csa
design
includ
alisporivir
previous
known
debio
although
phase
phase
ii
clinic
trial
conduct
alisporivir
demonstr
inhibit
hcv
across
differ
genotyp
high
genet
barrier
resist
clinic
develop
compound
pursu
presum
due
rapid
develop
directact
antivir
drug
daa
hcv
howev
cypa
host
cell
factor
use
virus
differ
famili
coronavirus
hiv
suggest
cypa
antagonist
potenti
develop
broadspectrum
antivir
although
natur
preexist
mutat
hiv
capsid
protein
cypa
interact
partner
would
limit
broad
clinic
use
compound
class
cypaknockout
mice
human
cell
fulli
viabl
therefor
possibl
toxic
associ
cypa
inhibit
low
anoth
exampl
hdf
promot
viral
replic
mirna
preferenti
express
hepatocyt
primari
host
cell
hcv
regul
lipid
metabol
also
bind
sever
region
hcv
genom
notabl
two
region
close
end
stimul
rna
replic
soon
discoveri
hdf
hcv
antisensebas
oligonucleotid
approach
known
antagomir
develop
sequest
infect
cell
therebi
blunt
hcv
replic
approach
well
toler
vitro
vivo
impos
high
genet
barrier
resist
howev
studi
mice
identifi
mirna
tumour
suppressor
rais
concern
inhibit
moreov
given
challeng
deliveri
antagomir
best
knowledg
one
clinic
candid
regulu
therapeut
nacetylgalactosamineconjug
oligonucleotid
antagon
target
hepatocyt
pursu
combin
differ
approv
investig
daa
owe
higher
autonomi
bacteria
compar
virus
target
host
cell
pathway
rather
individu
factor
frequent
hdt
approach
form
program
cell
death
character
nuclear
fragment
chromatin
condens
cell
shrinkag
cell
membran
bleb
control
enzym
known
caspas
usual
phagocyt
remov
apoptot
bodi
without
caus
inflamm
cellautonom
process
facilit
elimin
recycl
cellular
compon
damag
organel
essenti
mainten
cellular
function
stress
includ
infecti
stress
mammalian
target
rapamycin
mtor
inhibitor
use
clinic
prevent
transplant
reject
supplementari
inform
tabl
caus
agent
tb
mycobacterium
tuberculosi
mtb
persist
macrophag
subvert
multipl
intracellular
antimicrobi
mechan
mtb
replic
within
earli
phagosom
prevent
fusion
lysosom
counteract
acidif
escap
host
cytosol
inhibit
host
cell
apoptosi
autophagi
caus
host
cell
lysi
consequ
mtb
replic
macrophag
even
induc
transform
epithelioid
giant
cell
well
foami
cell
rich
cholesterol
store
lipid
bodi
import
carbon
sourc
mtb
promin
cellintrins
biolog
pathway
within
macrophag
target
numer
hdt
candid
autophagi
use
host
defenc
strategi
numer
bacteri
pathogen
solubl
mediat
essenti
host
defenc
mtb
includ
main
activ
macrophag
box
stimul
autophagi
mtb
inhibit
autophagi
mean
lipid
mannos
cap
lipoarabinomannan
manlam
lipid
c
earli
secretori
antigen
secret
system
product
mycobacteri
virul
factor
encod
ei
gene
region
overcom
mtb
resist
kill
macrophag
promot
mtb
entri
autophag
compart
divers
rang
proautophag
drug
propos
tb
manag
hdt
compound
compris
small
molecul
belong
sever
pharmacolog
group
fig
supplementari
inform
tabl
mani
approv
divers
indic
diabet
cardiovascular
disord
hypertens
despit
highli
amen
target
small
compound
autophagi
induc
current
readi
clinic
trial
one
hand
due
limit
avail
detail
pharmacokinet
drug
hand
relat
preclin
test
tb
best
studi
autophagi
induc
rapamycin
sirolimu
reduc
replic
mtb
macrophag
howev
rapamycin
also
caus
profound
immun
suppress
metabol
cytochrom
enzym
strongli
induc
antitb
drug
rifampin
also
known
rifampicin
warrant
caution
use
rapamycin
combin
rifampin
moreov
reactiv
latent
tb
infect
ltbi
upon
rapamycin
therapi
argu
priorit
hdt
variou
screen
mtbinfect
macrophag
also
identifi
anticonvuls
carbamazepin
valproat
select
serotonin
uptak
inhibitor
fluo
xetin
epiderm
growth
factor
inhibitor
gefitinib
autophagi
induc
affect
mtb
replic
calcium
channel
blocker
verapamil
also
induc
autophagi
prove
efficaci
adjunct
tb
chemotherapi
notabl
deliv
combin
firstlin
drug
rifampin
newli
develop
antitb
diarylquinolin
bedaquilin
mous
model
dose
toxic
human
current
promis
drug
induc
autophagi
promot
phagosom
matur
mtbinfect
cell
oral
biguanid
metformin
wide
use
treatment
type
diabet
metformin
activ
monophosphateactiv
protein
kinas
ampk
interfer
mitochondri
respiratori
chain
promot
product
reactiv
oxygen
speci
ro
subsequ
mtb
kill
human
murin
macrophag
certain
extent
metformin
restrict
bacillari
growth
murin
pulmonari
tb
given
widespread
applic
accept
safeti
profil
metformin
seem
readi
enter
clinic
trial
hdt
tb
drug
may
overcom
inhibit
phagosom
matur
mtbinfect
macrophag
tyrosin
kinas
inhibitor
cholesterollow
agent
tyrosin
kinas
inhibitor
target
fusion
protein
bcrabl
imatinib
restrict
mtb
replic
arrest
prolifer
restor
apoptosi
myeloid
cell
approv
treatment
chronic
myeloid
leukaemia
statin
lovastatin
simvastatin
atorvastatin
inhibit
coenzym
reductas
hmgcoa
ratelimit
enzym
cholesterol
biosynthesi
pathway
commonli
indic
patient
suffer
vascular
disord
besid
phagosom
matur
statin
trigger
autophagi
mtbinfect
macro
phage
also
limit
lipid
bodi
biogenesi
therebi
restrict
gener
foami
cell
support
mtb
persist
statininduc
effect
lead
kill
intracellular
mtb
innat
immun
respons
compris
cell
mechan
continu
present
activ
within
minut
hour
infect
suppress
replic
spread
invad
pathogen
addit
innat
immun
respons
provid
import
support
longlast
adapt
humor
cellular
immun
respons
function
brought
recruit
immun
cell
site
infect
frequent
mediat
chemokin
cytokin
present
pathogenspecif
antigen
recognit
remov
pathogen
special
white
blood
cell
activ
complement
system
although
mechan
relev
viral
infect
hostdirect
therapi
hdt
distinct
cytokin
interferon
ifn
best
studi
ifn
gene
identifi
group
three
class
type
ifn
includ
type
ii
produc
activ
cell
natur
killer
nk
cell
type
iii
ifn
target
mucos
epitheli
cell
liver
upon
bind
cognat
receptor
cytokin
induc
signal
cascad
lead
activ
sever
hundr
ifnstimul
gene
isg
one
hand
isg
enhanc
adapt
immun
exampl
upregul
major
histocompat
complex
class
mhci
thu
antigen
present
hand
mani
gene
contribut
directli
indirectli
antivir
state
cell
net
result
ifntreat
cell
bare
abl
infect
virus
properti
reflect
name
cytokin
interfer
inhibit
viru
infect
replic
mediat
mani
way
includ
shutdown
rna
translat
enhanc
rna
degrad
cell
growth
arrest
addit
sever
isg
direct
antivir
effect
bone
marrow
stromal
antigen
also
known
tetherin
transmembran
protein
resid
cell
surfac
interact
envelop
viru
hiv
thu
tether
viru
particl
plasma
membran
prevent
releas
infect
cell
type
ii
crucial
defenc
intracellular
bacteria
protozoa
xenobioticmetabol
enzym
oxid
drug
facilit
elimin
ltbi
vast
major
mycobacterium
tuberculosisinfect
individu
remain
healthi
although
tuberculosi
elimin
contain
firstlin
drug
includ
isoniazid
rifampin
pyrazinamid
ethambutol
constitut
standard
therapi
drugsensit
tuberculosi
tb
macrophag
vitro
vivo
experiment
mous
model
treatment
simvastatin
combin
canon
drug
isoniazid
rifampin
pyrazinamid
shorten
therapi
durat
murin
tb
moreov
retrospect
investig
larg
patient
cohort
compris
new
tb
case
control
patient
reveal
risk
tb
reactiv
upon
statin
intak
studi
prompt
epidemiolog
observ
statin
improv
clinic
outcom
respiratori
infect
widespread
use
good
safeti
profil
statin
remain
attract
hdt
candid
tb
enhanc
immun
respons
approach
hdt
describ
focus
enhanc
cellintrins
antimicrobi
mechan
aim
control
ideal
clear
infect
sever
approach
also
pursu
target
either
innat
box
adapt
immun
respons
viral
bacteri
infect
first
approv
ifnfre
daabas
therapi
chronic
hepat
c
late
earli
ifn
therapi
primarili
use
treatment
patient
infect
hcv
countri
unabl
afford
highcost
daa
treatment
still
use
purpos
cell
treat
cytokin
mount
antivir
state
thu
protect
viral
infect
ifn
simultan
import
stimulatori
effect
adapt
immun
respons
addit
new
strategi
current
emerg
base
use
individu
engin
cell
design
break
persist
viru
infect
treatment
patient
chronic
hepat
b
hepat
c
supplementari
inform
tabl
includ
ifn
recombin
synthet
type
ifn
recombin
roferona
intron
must
administ
antivir
compound
structur
mimic
nucleosid
abort
chain
elong
upon
incorpor
grow
nucleic
acid
chain
tlr
membranebound
protein
express
macrophag
dendrit
cell
sens
pathogenassoci
molecular
pattern
pamp
singleor
doublestrand
rna
bacteri
unmethyl
cpg
dna
recruit
adaptor
molecul
lead
activ
transcript
factor
nuclear
activ
protein
well
interferon
regulatori
factor
case
induc
proinflammatori
cytokin
case
type
interferon
dendrit
cell
resid
skin
mucosa
signal
cascad
induc
upon
bind
rna
rigi
subcutan
inject
sever
time
week
well
pegasi
pegintron
inject
week
success
therapi
measur
sustain
virolog
respons
svr
consider
increas
pegifn
combin
ribavirin
primarili
owe
prevent
viru
relaps
therapi
termin
multipl
paramet
affect
svr
rate
includ
high
bodi
mass
index
liver
cirrhosi
genotyp
infect
hcv
addit
polymorph
gene
encod
one
type
iii
ifn
also
known
highli
predict
outcom
therapi
well
acut
infect
underli
reason
clearli
defin
major
limit
ifnbas
therapi
numer
side
effect
includ
influenzalik
symptom
fever
fatigu
depress
bone
marrow
suppress
exacerb
autoimmun
mainli
due
ribavirin
haemolyt
anaemia
side
effect
particularli
pronounc
ifn
discontinu
aim
reduc
system
effect
clinic
trial
conduct
express
receptor
ifn
limit
mucos
epitheli
cell
human
liver
howev
svr
rate
patient
chronic
hepat
c
treat
similar
although
extrahepat
advers
event
less
frequent
patient
treat
given
compar
efficaci
type
iii
type
ifn
presum
also
due
rapid
develop
ifnfre
treatment
modal
clinic
develop
chronic
hepat
c
pursu
also
approv
treatment
adult
chronic
infect
hbv
children
howev
disappointingli
low
svr
rate
achiev
defin
loss
hbv
surfac
antigen
hbsag
without
product
hbsagspecif
antibodi
refer
hbsag
seroconvers
sustain
control
coval
close
circular
dna
cccdna
liver
fig
nondetect
viral
dna
serum
although
combin
hbvspecif
nucleosid
analogu
enhanc
svr
rate
overal
respons
still
seem
depend
chosen
nucleosid
analogu
despit
drawback
certain
advantag
current
avail
chemotherapi
notabl
lack
drug
resist
major
concern
especi
lamivudin
finit
treatment
cours
usual
week
induct
durabl
virolog
respons
particularli
hbsag
seroconvers
also
shown
antivir
activ
ref
howev
area
research
somewhat
neglect
role
ifn
control
hiv
infect
recent
receiv
increas
attent
exampl
administr
rhesu
macaqu
model
infect
pathogen
strain
simian
immunodefici
viru
siv
prevent
system
infect
continu
treatment
dampen
host
ifn
respons
concomit
reduc
antivir
gene
express
addit
block
type
ifn
receptor
reduc
antivir
gene
express
enhanc
siv
replic
spread
acceler
cell
loss
interestingli
phase
ii
clinic
trial
patient
infect
reveal
signific
albeit
moder
reduct
plasma
viral
load
week
treatment
observ
suggest
administr
supraphysiolog
level
ifn
patient
infect
help
control
viru
replic
howev
develop
numer
strategi
avoid
detect
pattern
recognit
receptor
block
ifninduc
restrict
factor
thu
limit
antihiv
activ
moreov
increas
activ
seem
contribut
immun
activ
immun
dysfunct
hivposit
patient
therefor
dampen
product
although
may
detriment
effect
suppress
hiv
replic
might
reduc
immun
activ
thu
sever
diseas
variou
approach
develop
boost
endogen
innat
ifn
respons
reli
activ
tolllik
receptor
tlr
one
tlr
agonist
approv
antivir
therapi
imidazoquinolin
imiquimod
imiquimod
given
topic
cream
formul
local
treatment
extern
genit
perian
wart
frequent
caus
infect
human
papillomavirus
hpv
imiquimod
sens
trigger
product
variou
cytokin
notabl
tumour
necrosi
factor
tnf
caus
reduct
viral
load
wart
size
addit
imiquimod
activ
langerhan
cell
migrat
local
lymph
node
promot
adapt
immun
respons
treatment
durat
maximum
week
clearanc
rate
recurr
rate
major
challeng
success
control
hiv
infect
persist
provir
integr
dna
rest
cell
latenc
reservoir
fig
pronounc
immun
suppress
result
infect
differ
strategi
current
pursu
tackl
challeng
includ
shock
kill
approach
latent
reactiv
cell
allow
kill
cell
immun
effector
function
one
exampl
stimul
rigi
pathway
approv
retino
acid
deriv
acitretin
treatment
activ
hiv
transcript
rigi
express
turn
sens
hiv
rna
thu
mount
ifn
respons
preferenti
induc
apoptosi
hivinfect
cell
although
earli
clinic
studi
drug
acitretin
trigger
transcript
provir
genom
rais
hope
strategi
use
revers
latenc
extent
strategi
reduc
viral
reservoir
size
remain
determin
timothi
ray
brown
hiv
infect
diagnos
acut
myeloid
leukaemia
receiv
two
stem
cell
transplant
donor
homozyg
mutat
hiv
coreceptor
first
stem
cell
transplant
brown
stop
antiretrovir
medic
hiv
becam
undetect
remain
viru
free
patient
achiev
steril
cure
car
artifici
cell
receptor
often
compos
singlechain
variabl
fragment
scfv
fuse
transmembran
domain
endodomain
transmit
activ
signal
upon
antigen
bind
extracellular
scfv
immun
cell
express
car
defin
specif
mediat
scfv
releas
inhibit
protect
immun
mediat
coinhibitori
molecul
antimicrobi
peptid
amp
divers
group
molecul
show
broadspectrum
antibiot
activ
amp
attach
insert
membran
bilay
lead
format
pore
destabil
membran
induc
lysi
amp
also
penetr
microbi
cell
bind
intracellular
molecul
essenti
surviv
microorgan
timefram
requir
chang
posit
identif
mycobacterium
tuberculosi
neg
sputum
cultur
usual
monitor
month
initi
therapi
repres
valid
predictor
durabl
tuberculosi
cure
hope
achiev
hiv
erad
immunebas
therapi
reactiv
famou
berlin
patient
howev
aim
function
cure
immun
control
hiv
without
erad
seem
realist
one
approach
use
immun
cell
engin
express
molecularli
clone
cell
receptor
recogn
hiv
epitop
howev
approach
limit
mani
highli
effect
cell
identifi
patient
recogn
hiv
epitop
context
uncommon
human
leukocyt
antigen
hla
allel
therefor
applic
major
infect
individu
common
hla
allel
moreov
owe
high
level
hiv
genom
variabl
particularli
patient
longterm
infect
latent
hiv
infect
compris
escap
mutant
target
cell
receptor
limit
overcom
use
cell
express
chimer
antigen
receptor
car
review
ref
howev
despit
promis
vitro
vivo
result
clinic
valu
approach
hivinfect
individu
remain
determin
chronic
hepat
b
lead
exhaust
cell
induc
increas
express
checkpoint
inhibitor
program
cell
death
ligand
immun
effector
cell
mous
model
hepat
b
therapi
antibodi
increas
hbcagspecif
interferon
gamma
product
intrahepat
cell
revers
exhaust
cell
phenotyp
led
clearanc
hbv
potenti
efficaci
checkpoint
blockad
hepat
b
underscor
addit
studi
show
effect
chronic
viral
infect
exampl
treatment
hcvinfect
chimp
antibodi
enhanc
antivir
cell
respons
reduc
viraemia
similarli
treatment
sivinfect
macaqu
antibodi
led
signific
reduct
plasma
viral
load
prolong
surviv
antimicrobi
capac
macrophag
enhanc
activ
cytokin
vitamin
factor
stimul
cell
autonom
respons
drive
product
antimicrobi
peptid
amp
fig
supplementari
inform
tabl
immuneenhanc
strategi
usual
exert
pleiotrop
effect
integr
stimul
antimicrobi
immun
rectif
pathway
block
alter
mtb
besid
macrophag
dendrit
cell
dc
neutrophil
also
harbour
mtb
howev
hdt
approach
target
cell
far
envisag
mix
effect
macrophag
report
vitamin
vitamin
mechanist
vitamin
induc
amp
cathelicidin
trigger
ro
product
promot
autophagi
infect
macrophag
amp
induct
potenti
coadministr
histon
deacetylas
inhibitor
phenylbutyr
fig
although
previou
clinic
trial
assess
benefit
vitamin
tb
provid
inconclus
result
sever
trial
vitamin
adjunct
tb
chemotherapi
notabl
firstlin
drug
ongo
microbicid
effect
vitamin
recogn
decad
attribut
direct
effect
mtb
well
modul
host
immun
vitamin
deriv
notabl
alltran
retino
acid
restrict
mtb
growth
macrophag
induc
phagosom
acidif
rat
mice
alltran
retino
acid
reduc
mtb
load
modul
cellular
immun
inflamm
supplement
vitamin
shown
benefici
outcom
patient
care
select
minim
effect
dosag
vitamin
may
form
basi
hdt
tb
sever
cytokin
notabl
tnf
stimul
antimicrobi
activ
macrophag
fig
promot
phagosom
matur
autophagi
tnf
augment
respons
upregul
rosmedi
kill
increas
amp
synthesi
upregul
tnf
receptor
tnfr
express
restrict
product
type
ifn
primarili
antagonist
tb
howev
hyperinflamm
downstream
excess
cytokin
stimul
promot
diseas
exacerb
see
high
dose
tnf
caus
necroptot
macrophag
death
extra
cellular
bacteri
replic
current
cytokinebas
hdt
approach
mostli
involv
modul
tnf
exampl
deliveri
aerosol
patient
tb
shown
reduc
time
sputum
convers
without
consist
improv
chest
radiolog
outcom
small
trial
carri
cohort
patient
drugresist
tb
adjunct
therapi
addit
facilit
bacteri
kill
improv
lung
repair
howev
cytokinebas
hdt
strategi
modul
tnf
adjunct
canon
chemotherapi
seem
promis
consider
shorten
therapi
durat
improv
patholog
limit
tb
relaps
experiment
model
detail
wherea
type
ifn
includ
qualifi
hdt
sever
viral
infect
seem
counterintuit
bacteri
diseas
tb
given
associ
diseas
progress
howev
given
adjunct
convent
chemotherapi
might
provid
interest
treatment
option
resuscit
dormant
mtb
replic
bacilli
suscept
firstand
secondlin
tb
drug
exampl
isoniazid
rifampin
fluoroquinolon
riskbenefit
shock
kill
approach
current
explor
hiv
infect
also
consid
difficulttotreat
form
tb
express
inhibitori
molecul
upregul
persist
antigen
exposur
occur
chronic
infect
includ
tb
cancer
sepsi
mesenchym
stem
cell
msc
selfrenew
multipot
cell
abl
differenti
variou
cell
type
also
endow
immun
tissu
repair
function
extens
drugresist
tb
xdr
tb
form
tuberculosi
tb
caus
bacilli
resist
firstlin
drug
isoniazid
rifampin
known
multidrugresist
tb
mdr
tb
fluoroquinolon
levofloxacin
moxifloxacin
least
one
three
inject
secondlin
drug
amikacin
kanamycin
capreomycin
therapi
xdr
tb
often
fail
cytokin
product
induc
lymphocyt
apoptosi
impair
cell
immun
promot
mtb
replic
subsequ
tissu
damag
build
impress
success
achiev
cancer
immunotherapi
checkpoint
blockad
consid
tb
therapi
fig
includ
monoclon
antibodi
mab
specif
nivolumab
pembrolizumab
cytotox
lymphocyt
associ
protein
ipilimumab
cell
express
gradual
decreas
canon
chemotherapi
concurr
increas
h
cell
respons
moreov
express
macrophag
neutrophil
report
patient
tb
link
impair
cell
natur
killer
nkt
cell
function
vitro
treatment
mab
cell
cultur
deriv
patient
tb
reduc
immunosuppress
block
cell
apoptosi
restor
product
trigger
kill
mtbinfect
macrophag
similarli
increas
surfac
express
also
report
tb
checkpoint
receptor
found
highli
express
cell
nk
cell
lung
nonhuman
primat
progress
activ
tb
anim
ltbi
observ
suggest
chang
express
pattern
influenc
diseas
outcom
mtb
replic
final
blockad
anoth
checkpoint
receptor
cell
increas
propens
myeloid
cell
kill
mtb
effect
link
increas
product
cell
increas
product
mtbinfect
macrophag
moreov
releas
cell
exhaust
caus
blockad
improv
mtb
control
mice
chronic
infect
tb
howev
intervent
use
checkpoint
inhibitor
gener
warrant
caution
block
inhibitori
effect
cell
therebi
increas
capac
lunghom
subset
cell
caus
extens
lung
patholog
murin
model
tb
final
therapi
reactiv
ltbi
suggest
checkpoint
blockad
consid
adjunct
canon
tb
chemotherapi
releas
immun
suppress
also
achiev
cellular
therapi
mesenchym
stem
cell
msc
although
msc
may
use
nich
dormant
mtb
propens
msc
induc
regulatori
phenotyp
dc
cell
promot
tissu
repair
render
attract
tool
hdt
safeti
approach
demonstr
phase
trial
patient
multidrugresist
tb
mdr
tb
extens
drugresist
tb
xdr
tb
receiv
infus
singl
dose
autolog
msc
higher
cure
rate
radiolog
improv
observ
small
cohort
studi
compris
patient
mdr
tb
deliveri
msc
readi
enter
phase
ii
clinic
trial
adjunct
therapi
drugresist
tb
although
earli
death
sepsi
often
due
cytokinemedi
hyperinflamm
numer
studi
provid
compel
evid
sepsi
protract
last
longer
day
evolv
highli
immunosuppress
state
major
septic
death
occur
new
immunoadjuv
therapi
need
restor
host
immun
improv
surviv
current
one
activ
area
sepsi
research
fig
supplementari
inform
tabl
two
immuneenhanc
cytokin
alreadi
undergon
small
therapeut
trial
sepsi
granulocytemacrophag
colonystimul
factor
gmcsf
gmcsf
stimul
gener
granulocyt
monocyt
macrophag
predomin
function
activ
monocyt
macrophag
although
small
earli
studi
gmcsf
patient
protract
sepsi
seem
promis
subsequ
trial
fail
demonstr
consist
benefit
recent
investig
target
therapi
gmcsf
patient
immunosuppress
phase
sepsi
studi
patient
sepsi
low
monocyt
hladr
express
gmcsf
therapi
shorten
durat
mechan
ventil
improv
sever
ill
score
reduc
length
intens
care
unit
icu
hospit
stay
gmcsf
also
efficaci
studi
immunosuppress
paediatr
patient
sepsi
identifi
measur
ex
vivo
wholeblood
lipopolysaccharid
lp
stimul
tnf
product
gmcsf
administr
patient
improv
ex
vivo
lpsstimul
wholeblood
tnf
product
decreas
risk
hospitalacquir
infect
base
encourag
result
multicentr
trial
gmcsf
sepsi
current
way
also
receiv
renew
interest
hdt
patient
immunosuppress
phase
sepsi
multicentr
trial
trauma
patient
mani
develop
sepsi
reveal
patient
treat
fewer
infectionrel
death
also
fewer
overal
death
report
group
studi
nine
patient
sepsi
decreas
monocyt
hladr
express
reduc
ex
vivo
lpsstimul
wholeblood
tnf
treat
eight
patient
benefit
restor
monocyt
function
surviv
septic
insult
also
test
eight
patient
invas
fungal
infect
markedli
improv
monocyt
hladr
express
enhanc
abil
leukocyt
produc
proinflammatori
cytokin
observ
trial
immunosuppress
patient
bacteri
sepsi
ongo
perhap
excit
immunoadjuv
agent
sepsi
cytokin
essenti
surviv
cell
multipl
benefici
effect
host
immun
includ
prolifer
activ
cell
also
increas
surfac
express
cell
adhes
molecul
therebi
facilit
traffick
cell
site
infect
also
counteract
sepsisinduc
apoptosi
lymphocyt
antiapoptot
effect
particularli
import
sever
deplet
immun
effector
cell
includ
cell
b
cell
dc
pathophysiolog
hallmark
sepsi
multipl
studi
independ
laboratori
shown
improv
surviv
variou
clinic
relev
anim
model
sepsi
importantli
shown
effect
revers
cell
dysfunct
circul
immun
cell
patient
septic
shock
far
given
patient
treatment
variou
disord
consist
increas
circul
absolut
lymphocyt
count
well
toler
patient
aid
restor
gastrointestinalassoci
lymphoid
tissu
lead
decreas
circul
marker
inflamm
effect
may
also
particularli
help
patient
sepsi
loss
gut
barrier
integr
sepsi
thought
facilit
transloc
bacteria
andor
lp
circul
therebi
drive
inflammatori
respons
also
administ
compassion
basi
patient
lymphopenia
john
cunningham
jc
virusinduc
progress
multifoc
leukoencephalopathi
set
increas
lymphocyt
count
decreas
jc
viru
load
surviv
multicentr
clinic
trial
sepsi
current
ongo
tabl
postmortem
studi
patient
sepsi
show
find
consist
cell
exhaust
includ
upregul
immun
cell
sever
impair
cytokin
secret
importantli
multipl
independ
group
report
overexpress
circul
cell
patient
sepsi
incub
peripher
blood
mononuclear
cell
specif
antibodi
restor
impair
cytokin
product
decreas
sepsisinduc
apoptosi
moreov
anim
model
sepsi
shown
delay
administr
anti
bodi
improv
surviv
given
surpris
overlap
immunolog
deficit
cancer
sepsi
remark
success
inhibit
cancer
immunotherapi
strong
rational
trial
antibodi
sepsi
small
multicentr
dose
safeti
trial
patient
sepsi
recent
complet
antibodi
one
four
dengu
viru
denv
serotyp
specif
block
infect
serotyp
enhanc
infect
nonhomolog
serotyp
bind
viru
particl
permit
cellular
uptak
via
receptor
myeloid
cell
known
antibodydepend
enhanc
enzym
cleav
glycosid
linkag
neuramin
acid
case
influenza
viru
enzym
express
surfac
virion
requir
effici
viru
releas
infect
cell
anoth
encourag
approach
boost
immun
patient
sepsi
treatment
thymosin
acid
polypeptid
origin
deriv
mous
thymic
extract
supplementari
inform
tabl
although
exact
mechan
action
thymosin
unknown
current
thought
function
part
tlr
agonist
thymosin
known
enhanc
cell
dc
function
increas
product
improv
antibodi
respons
similar
treatment
inhibitor
thymosin
shown
benefit
treatment
cancer
infecti
diseas
thymosin
show
efficaci
improv
surviv
multicentr
random
control
trial
patient
sepsi
compar
patient
treat
placebo
patient
treat
thymosin
increas
monocyt
hlaantigen
relat
dr
express
decreas
mortal
base
result
larger
multicentr
trial
thymosin
sepsi
initi
major
challeng
select
antivir
antibacteri
therapi
time
administr
exampl
acut
viral
infect
diseas
symptom
manifest
viraemia
alreadi
declin
select
antivir
therapi
often
initi
late
howev
suppress
exacerb
diseas
symptom
trigger
pathogen
later
time
point
reduc
morbid
mortal
hdt
requir
detail
understand
pathogenhost
interact
hold
promis
reduc
diseas
symptom
level
selflimit
infect
devast
consequ
viral
infect
frequent
aris
excess
often
uncontrol
releas
proinflammatori
cytokin
cytokin
storm
trigger
multipl
mechan
includ
hyperactiv
tlr
exampl
includ
dengu
haemorrhag
fever
dengu
shock
syndrom
often
caus
secondari
infect
heterolog
serotyp
dengu
viru
denv
seriou
case
character
uncontrol
hyperproduct
cytokin
chemokin
tnf
ifn
cc
motif
chemokin
cxc
motif
chemokin
ultim
lead
vascular
leakag
shock
syndrom
key
driver
cytokin
storm
seem
highlevel
viraemia
ligat
denvimmunoglobulin
complex
myeloid
mast
cell
secret
version
viral
protein
drive
excess
proinflammatori
respons
reduc
antiinflammatori
one
bind
induc
product
cytokin
detect
cours
sever
dengu
diseas
enhanc
vascular
permeabl
block
activ
antagonist
antibodi
markedli
reduc
vascular
leakag
vitro
mous
model
denv
infect
moreov
autophagi
induct
endotheli
cell
seem
requir
vascular
leakag
block
autophagi
inhibitor
final
denv
also
promot
vascular
leakag
induc
express
enzym
sialidas
heparanas
degrad
glycocalyx
layer
line
endothelium
lumin
side
thu
diminish
barrier
function
enhanc
fluid
extravas
although
best
knowledg
clinic
trial
yet
conduct
result
hold
great
promis
suppress
exacerb
inflamm
target
ligand
receptor
altern
strategi
hdtbase
symptomat
treatment
sever
dengu
diseas
base
immunosuppress
therapi
steroid
prednisolon
far
met
limit
success
concept
modul
inflamm
also
evalu
influenza
viru
infect
cytokin
storm
caus
acut
sometim
fatal
immunemedi
pulmonari
injuri
propos
acut
lung
injuri
trigger
infect
respiratori
virus
bacteria
induc
via
ro
product
pathogen
oxid
lipid
activ
induc
cytokin
storm
consist
mous
mutant
protect
lethal
challeng
mouseadapt
influenza
viru
strain
notabl
antagonist
eritoran
investig
drug
treatment
sever
sepsi
consist
decreas
lung
patholog
clinic
symptom
variou
vivo
influenza
model
encourag
result
togeth
wellestablish
safeti
profil
eritoran
observ
given
day
influenza
viru
infect
mice
qualifi
compound
interest
candid
prevent
sever
influenza
sever
altern
strategi
suppress
influenza
virusinduc
cytokin
storm
current
pursu
one
approach
base
agonist
receptor
aalr
compound
reduc
mortal
influenzainfect
mice
reduc
mortal
given
combin
neuraminidas
inhibitor
oseltamivir
antiinflammatori
effect
aalr
mediat
least
part
limit
autoamplif
loop
plasmacytoid
dc
main
produc
cytokin
cyclooxygenas
cox
catalys
convers
arachidon
acid
prostaglandin
modul
immun
respons
inflamm
hdt
target
sever
influenza
benefici
effect
report
inhibitor
target
combin
two
inhibitor
celecoxib
mesalazin
neuraminidas
inhibitor
zanamivir
studi
tripl
regimen
surviv
rate
mice
infect
highli
lethal
influenza
viru
strain
significantli
improv
p
surviv
time
p
inflamm
marker
p
rel
anim
receiv
neuraminidas
inhibitor
howev
systemat
evalu
treatment
modal
patient
infect
influenza
viru
still
lack
peroxisom
proliferatoractiv
ppar
nuclear
receptor
protein
upon
bind
specif
ligand
transloc
nucleu
induc
express
multipl
gene
involv
cell
differenti
metabol
biolog
process
form
cell
death
result
loss
membran
integr
uncontrol
releas
cellular
product
extracellular
space
accident
regul
necrosi
inflammatori
type
cell
injuri
affect
tissu
integr
detriment
organ
statin
hdt
assess
clinic
trial
patient
infect
influenza
viru
antiinflammatori
properti
result
conflict
approach
antiinflammatori
treatment
base
agonist
peroxisom
proliferatoractiv
consid
promis
target
among
three
ppar
subtyp
sever
studi
mous
model
shown
agonist
decreas
inflamm
influenza
morbid
whether
approach
effect
human
remain
determin
increas
evid
suggest
neutrophil
major
role
sever
lung
patholog
influenza
viru
infect
although
cell
contribut
protect
influenza
viru
infect
heighten
neutrophil
recruit
correl
virul
given
influenza
viru
strain
reason
inhibitor
neutrophil
chemotaxi
develop
danirixin
clinic
advanc
inhibitor
chemokin
receptor
drive
neutrophil
migrat
danirixin
develop
treatment
chronic
obstruct
pulmonari
diseas
found
well
toler
induc
major
safeti
concern
base
result
phase
ii
clinic
trial
current
recruit
patient
receiv
danirixin
either
alon
combin
neuraminidas
inhibitor
oseltamivir
therapi
influenza
viru
infect
adult
tb
pathophysiolog
character
nonresolv
inflamm
consequ
host
failur
elimin
mtb
inflammatori
pathway
involv
proand
antiinflammatori
mediat
primarili
cytokin
lipid
sequenti
turn
tb
accordingli
mechan
restrict
promot
inflamm
relev
distinct
diseas
stage
specif
infect
site
imbal
respons
rather
sole
exacerb
proinflammatori
respons
characterist
featur
tb
differ
form
lesion
solid
fibrot
miner
caseat
granuloma
well
caviti
foci
pneumonia
coexist
within
patient
even
within
singl
lesion
inflammatori
mediat
segreg
distinct
region
therefor
concurr
applic
proand
antiinflammatori
intervent
may
becom
necess
therapi
concept
spatiotempor
coexist
hyperand
hypoinflamm
pose
great
challeng
bare
begun
address
experiment
current
hdt
approach
compris
small
molecul
biolog
target
antiand
proinflammatori
pathway
adjunct
measur
tb
therapi
fig
supplementari
inform
tabl
metabolit
arachidon
acid
modul
inflamm
cell
death
immun
investig
hdt
tb
cox
product
prostaglandin
proapoptot
eicosanoid
protect
necrot
cell
death
mycobacteri
infect
mtb
skew
arachidon
acid
metabol
pathway
toward
lipoxygenas
lox
activ
gener
pronecrot
lipoxin
leukotrien
modul
axi
zileuton
clinic
licens
inhibitor
treatment
asthma
nasal
applic
restrict
lung
patholog
murin
tb
fig
combin
therapi
zileuton
boost
cytoprotect
product
limit
type
ifn
product
restrict
mtb
replic
balanc
level
probabl
involv
success
control
mtb
ltbi
compar
activ
tb
activ
tb
concentr
increas
abund
correl
extent
tissu
damag
mediat
neutrophil
ltbi
earli
product
seem
essenti
protect
wherea
heighten
level
later
stage
infect
impair
immun
defenc
promot
progress
diseas
cox
inhibitor
ibuprofen
aspirin
diclofenac
given
alon
combin
canon
tb
drug
limit
bacillari
load
prolong
surviv
tbsuscept
mice
addit
ibuprofen
direct
antitubercular
activ
fig
nonsteroid
antiinflammatori
drug
nsaid
ibuprofen
inhibit
product
enhanc
gener
addit
effect
mtbinduc
cell
death
also
show
antiinflammatori
function
nsaid
limit
pge
releas
induc
lipoxin
product
lower
tnf
abund
thu
like
amelior
local
inflamm
certain
nsaid
notabl
aspirin
alreadi
enter
clinic
trial
tb
ibuprofen
also
regist
phase
ii
clinic
trial
therapi
xdr
tb
interf
cytokin
signal
anoth
promis
hdt
warrant
consider
fig
sever
strategi
congruent
divers
cytokin
involv
control
tb
inflamm
envisag
blockad
cytokin
signal
reduc
local
influx
inflammatori
cell
achiev
target
tnf
tnf
crucial
cytokin
immun
defenc
tb
although
requir
granuloma
integr
ltbi
high
level
tnf
exacerb
patholog
observ
pave
way
sever
hdt
approach
tnf
level
decreas
restrict
exacerb
patholog
altern
achiev
better
drug
penetr
lesion
destabil
solid
eventu
fibrot
granuloma
facilit
kill
mtb
resuscit
dormant
bacteria
replic
activ
given
link
cell
death
propag
inflammatori
respons
mtb
infect
restrict
tnfinduc
necroptot
cell
death
infect
macrophag
deliveri
alisporivir
desipramin
could
limit
local
recruit
mtbpermiss
cell
alisporivir
desipramin
restrict
rosmedi
necrosi
block
cyclophilin
acid
sphingomyelin
respect
tnf
blocker
wide
use
patient
rheumatoid
arthriti
inflammatori
bowel
diseas
thu
readili
repurpos
hdt
tb
sever
case
mab
tnf
infliximab
adalimumab
shown
benefici
effect
lifethreaten
tb
etanercept
solubl
tnf
receptor
demonstr
modest
benefit
adjunct
therapi
tb
howev
contrast
etanercept
mab
tnf
reactiv
ltbi
destabil
granuloma
wherea
contraind
rheumatoid
arthriti
chronic
inflammatori
diseas
could
benefici
adjunct
therapi
tb
facilit
kill
metabol
activ
bacilli
may
repres
shock
kill
strategi
concentr
correl
sever
lung
damag
patient
tb
revert
normal
concentr
upon
chemotherapi
mab
inhibit
siltuximab
tocilizumab
clinic
use
rheumat
diseas
applic
biolog
associ
tb
reactiv
preclin
model
tb
therefor
one
hand
mab
pose
risk
reactiv
individu
ltbi
hand
suit
shock
kill
intervent
variou
class
drug
affect
tnf
signal
reactiv
ltbi
shown
potenti
hdt
tb
exampl
jak
inhibitor
tofacitinib
licens
patient
rheumatoid
arthriti
associ
reactiv
ltbi
impair
bacillari
contain
murin
tb
coadministr
tofacitinib
canon
chemotherapi
benefici
select
model
tb
suggest
activ
jak
inhibitor
influenc
pattern
inflamm
granulomat
respons
addit
approach
modul
tnf
signal
abund
includ
thalidomid
analogu
phosphodiesteras
pde
inhibitor
thalidomid
improv
treatment
outcom
pilot
studi
pulmonari
tb
howev
clinic
trial
test
adjunct
thalidomid
therapi
paediatr
tb
termin
owe
advers
event
includ
skin
rash
hepat
sever
neutropenia
thrombocytopenia
thalidomid
teratogen
thalidomid
analogu
better
safeti
profil
synthes
analogu
inhibit
signal
increas
camp
level
shown
benefici
effect
adjunct
canon
tb
chemotherapi
mous
rabbit
model
infect
compound
acceler
bacillari
clearanc
promot
lung
repair
pde
inhibitor
includ
cilostazol
inhibitor
sildenafil
inhibitor
show
similar
effect
nonspecif
pde
inhibitor
pentoxifyllin
unsuccess
tb
trial
despit
reduc
tnf
level
induc
tb
progress
administ
monotherapi
mous
model
advanc
pde
inhibitor
preclin
studi
complet
phase
trial
phase
ii
trial
plan
compar
mammalian
target
rapamycin
mtor
inhibitor
everolimu
thioredoxin
reductas
inhibitor
auranofin
vitamin
hdt
adjunct
standard
chemotherapi
acceler
cure
drugsensit
tb
anoth
approach
restrict
local
inflamm
includ
codeliveri
glucocorticoid
receptor
agonist
prednisolon
dexamethason
tb
chemotherapi
effect
glucocorticoid
immun
cell
multifacet
corticosteroid
reduc
releas
proinflammatori
mediat
notabl
tnf
restrict
migrat
inflammatori
cell
caus
apoptosi
patient
tb
intervent
benefici
counteract
inflamm
like
improv
drug
penetr
granuloma
foster
clearanc
metabol
activ
mtb
consequ
lesion
destabil
adjunct
treatment
glucocorticoid
began
five
decad
ago
patient
differ
form
diseas
includ
tb
mening
tb
pericard
pulmonari
tb
mani
case
corticosteroid
seem
improv
resolut
lesion
albeit
without
major
longterm
benefit
recent
metaanalysi
indic
glucocorticoid
receptor
agonist
mostli
reduc
tb
mortal
central
nervou
system
affect
notabl
tb
mening
benefit
glucocorticoid
depend
genotyp
patient
indic
diverg
effect
result
differ
pattern
inflammationgenotypespecif
hypoor
hyperinflamm
differ
patient
influenc
mtb
replic
metaregress
analysi
pulmonari
tb
reveal
addit
genotyp
effect
dosag
corticosteroid
affect
sputum
convers
patient
tb
phase
ii
clinic
trial
test
corticosteroid
combin
standard
chemotherapi
tb
patient
coinfect
hiv
indic
faster
sputum
convers
also
advers
event
high
dosag
studi
care
assess
risk
benefit
glucocorticoid
underway
deliveri
glucocorticoid
priorit
hdt
specif
patient
group
suffer
tb
aid
comorbid
use
prednison
nsaid
drug
meloxicam
prevent
immun
reconstitut
inflammatori
syndrom
iri
observ
patient
coinfect
hiv
mtb
reach
phase
iii
phase
ii
trial
stage
respect
similarli
glucocorticoid
receptor
agonist
dexamethason
phase
iiiii
phase
iv
trial
therapi
mening
tb
sepsi
tradit
consid
disord
caus
uncontrol
exacerb
host
inflammatori
respons
invad
pathogen
concept
logic
given
patient
sepsi
frequent
present
sign
overwhelm
inflamm
typifi
highspik
fever
shock
acut
respiratori
distress
discoveri
tnf
cytokin
reinforc
concept
morbid
mortal
sepsi
due
unbridl
cytokinemedi
host
respons
fact
inhibitor
tnf
prevent
death
anim
model
sepsi
caus
endotoxin
escherichia
coli
support
idea
morbid
sepsi
due
excess
cytokinemedi
inflamm
patient
sepsi
quickli
succumb
overwhelm
cytokinemedi
hyperinflammatori
respons
typic
exampl
type
diseas
format
caviti
granuloma
due
necrosi
follow
discharg
necrot
debri
includ
meningococcaemia
rapidli
invas
necrot
soft
tissu
infect
group
streptococci
necrot
pneumonia
caus
pantonvalentin
leukocidinsecret
staphylococcu
aureu
overwhelm
clostridia
difficil
coliti
patient
type
toxinmedi
catastroph
infect
may
benefit
anticytokinebas
therapi
block
mediat
highli
lethal
acut
inflammatori
respons
howev
small
subset
patient
sepsi
therapi
use
block
host
respons
pathogen
short
act
appli
earli
sepsi
use
patient
sepsi
manifest
evid
uncontrol
inflamm
although
previou
trial
drug
inhibit
activ
tnf
fail
show
benefit
gener
popul
patient
sepsi
indic
particular
subset
patient
sepsi
may
benefici
respons
regard
recent
reanalysi
deidentifi
data
phase
ii
trial
receptor
antagonist
anakinra
sever
sepsi
reveal
highli
signific
improv
surviv
subset
patient
concurr
hepatobiliari
dysfunct
dissemin
intravascular
coagul
dic
concomit
liver
injuri
dic
investig
specul
small
subset
patient
may
sepsisinduc
macrophag
activ
syndrom
character
uncontrol
macrophag
cell
activ
haemophagocytosi
mark
increas
circul
cytokin
hdt
target
inflamm
viral
infect
sepsi
share
similar
eritoran
agonist
well
advanc
clinic
trial
pipelin
either
aim
hyperinflammatori
phase
aim
system
effect
respect
antiinflammatori
strategi
inhibitor
intend
tb
viral
diseas
system
deliveri
glucocorticoid
immunosuppress
clinic
trial
tb
host
reaction
site
infect
pathogen
induc
variabl
tissu
chang
accord
site
entri
resid
specif
pathophysiolog
propens
spread
system
agent
caus
extens
remodel
affect
tissu
mtb
use
result
lesion
replic
hide
host
defenc
contrast
microorgan
spread
system
caus
sepsi
develop
strategi
skew
immun
stagespecif
global
manner
modul
host
immun
local
gener
manner
attract
hdt
option
tb
strategi
direct
toward
limit
granuloma
expans
instabl
rather
neoform
aim
augment
drug
penetr
lesion
balanc
inflammatori
respons
modifi
metabol
featur
immun
cell
facilit
tissu
repair
fig
supplementari
inform
tabl
spectrum
granuloma
differ
stage
patient
tb
demand
care
consider
spatiotempor
context
differ
approach
highlight
granuloma
reduc
blood
suppli
particularli
site
necrosi
therebi
restrict
access
chemotherapeut
site
mtb
infect
consequ
hdt
promot
vascular
perfus
improv
drug
deliveri
howev
strategi
may
equal
benefit
mtb
facilit
access
nutrient
permiss
host
cell
situat
somewhat
reminisc
neoplast
diseas
tumour
activ
promot
angiogenesi
improv
blood
suppli
allevi
local
hypoxia
late
stage
tumour
develop
outcom
vasculogenesisfocus
hdt
tb
like
depend
stage
diseas
treatment
object
name
interfer
either
angiogenesi
vascular
permeabl
patient
activ
tb
factor
induc
neovascular
notabl
vascular
endotheli
growth
factor
vegf
receptor
vegfr
abund
circul
propos
biomark
diseas
sever
bevacizumab
mab
vegf
approv
treatment
certain
cancer
sever
antibodi
target
vegf
vegfr
clinic
trial
anim
model
tb
vegf
vegfr
inhibitor
reveal
benefici
effect
given
combin
convent
drug
limit
bacteri
dissemin
boost
activ
drug
target
hypox
mtb
convers
risk
administr
biolog
without
concurr
chemotherapi
may
promot
tb
reactiv
bacillari
dissemin
addit
neovascular
vascular
dysfunct
emerg
anoth
common
cancer
tb
mtb
stimul
angiopoietin
axi
increas
blood
vessel
permeabl
vascular
endotheli
protein
tyrosin
phosphatas
inhibitor
molecul
close
relat
aerpio
therapeut
dephosphoryl
blunt
signal
endothelia
shown
restrict
mtb
replic
zebrafish
model
tb
result
indic
hdt
strategi
modul
vascular
biolog
stabil
permeabl
vasculatur
independ
infectioninduc
neovascular
limit
bacteri
growth
dissemin
granuloma
necrosi
cavit
hinder
access
chemotherapeut
agent
site
bacteri
replic
also
provid
microenviron
uniqu
physic
metabol
featur
oxygen
tension
gradual
decreas
granuloma
reach
hypox
valu
necrot
area
milieu
mtb
gain
increas
drug
resist
consequ
clonal
select
respons
local
monotherapi
owe
poor
drug
penetr
necrot
lesion
adjust
extracellular
cue
addit
bacilli
switch
fatti
acidbas
metabol
adopt
persist
phenotyp
host
adapt
hypox
advanc
glycat
end
product
age
enzymeindepend
glycat
protein
gener
age
recognit
cell
via
specif
receptor
rage
caus
inflamm
mdsc
heterogen
myeloid
cell
monocyt
granulocyt
appear
present
patholog
condit
suppress
cell
natur
killer
cell
macrophag
dendrit
cell
promot
expans
regulatori
cell
nutrientdepriv
microenviron
encompass
metabol
shift
oxid
phosphoryl
aerob
glycolysi
metabol
adjust
known
warburg
effect
well
establish
cancer
therapi
limit
aerob
glycolysi
includ
deliveri
antiglycolyt
agent
restrict
bioenerget
pathway
support
mtb
replic
moreov
interf
aktampk
signal
pathway
inhibit
glutamin
entri
tricarboxyl
acid
tca
cycl
thu
revert
local
warburg
metabol
metformin
ampk
activ
thu
efficaci
hdt
goe
beyond
effect
macrophag
discuss
potenti
interfer
immun
metabol
granuloma
less
wellexplor
still
interest
bioenerget
shift
encompass
gener
itacon
acid
structur
analogu
succin
control
tca
remodel
macrophag
antimycobacteri
function
addit
metabol
chang
granuloma
lead
accumul
advanc
glycat
end
product
age
affect
macrophag
death
activ
age
detect
tb
granuloma
pathway
regul
gener
age
could
potenti
hdt
target
promot
tissu
repair
granuloma
format
regress
lesion
occur
concurr
infect
tissu
balanc
tissu
repair
exacerb
patholog
depend
net
abund
mediat
matrix
metalloproteinas
mmp
caus
lung
patholog
factor
regul
mediat
tissu
inhibitor
metalloproteinas
timp
genet
associ
studi
support
crucial
role
mmp
lesion
progress
zincdepend
proteas
mainli
cleav
extracellular
matrix
mostli
collagen
link
earli
granuloma
format
lesion
progress
cavit
antibiot
doxycyclin
inhibit
therebi
restrict
exacerb
inflamm
tissu
damag
tb
deliveri
doxycyclin
limit
immunopatholog
promot
tissu
heal
lung
repair
doxycyclin
welldefin
pharmaco
kinet
pharmacodynam
profil
owe
broad
use
antiinfect
drug
may
therefor
potenti
rapidli
repurpos
tb
mmp
inhibitor
batimastat
marimastat
well
deserv
evalu
tb
howev
drug
show
advers
effect
musculo
skelet
system
upon
prolong
administr
therebi
question
overal
benefit
tb
therapi
hdt
interfer
host
cell
mechan
enhanc
immun
respons
reduc
exacerb
inflamm
balanc
host
reaction
site
patholog
hold
enorm
promis
select
symptomat
treatment
infecti
diseas
viral
infect
target
host
cell
factor
pathway
requir
given
viru
product
replic
spread
offer
opportun
broadspectrum
antivir
drug
futur
activ
focu
identif
suitabl
host
cell
factor
pathway
commonli
use
differ
virus
particularli
pandem
potenti
although
relev
inform
gener
recent
genet
screen
knowledg
remain
limit
equal
promis
hdt
aim
control
exacerb
inflamm
tissu
damag
discuss
approach
applic
numer
viral
bacteri
infect
could
use
adjunct
therapi
combin
select
pathogentarget
approach
pathway
involv
inflamm
well
understood
drug
alreadi
avail
allow
rapid
repurpos
infecti
diseas
control
accordingli
drug
current
hdt
clinic
trial
fall
categori
biomark
becom
essenti
part
futur
therapi
regim
henc
must
becom
integr
compon
r
activ
target
infecti
diseas
whether
host
pathogen
direct
biomark
indic
stage
infect
allow
monitor
treatment
success
failur
provid
inform
organ
involv
type
inflamm
permit
patient
stratif
select
hdt
person
regim
particularli
import
treatment
sepsi
advanc
immuno
phenotyp
allow
physician
determin
whether
patient
hyperor
hypoinflammatori
phase
disord
select
appropri
immunotherapi
similarli
hyperand
hypoinflammatori
lesion
coexist
tb
thu
requir
person
treatment
regim
addit
capac
identifi
particular
defect
innat
adapt
immun
immun
profil
cell
exhaust
increas
frequenc
regulatori
cell
myeloidderiv
suppressor
cell
mdsc
enabl
person
approach
correct
similar
impress
advanc
made
oncolog
combin
immunotherapi
hold
great
promis
next
major
advanc
infecti
diseas
moreov
identif
potenti
genet
predisposit
patient
instruct
adjunct
hdt
case
tb
genet
condit
lipid
mediat
mutat
enzymecod
gene
particularli
underor
overproduct
link
tnf
abund
affect
outcom
immunosuppress
therapi
patient
tb
mening
macrophag
major
target
hdt
tb
target
myeloid
cell
subset
neutrophil
also
contain
bacilli
associ
poor
diseas
outcom
may
lead
novel
approach
hdt
although
forese
bright
futur
hdt
newli
emerg
treatment
option
misinterpret
exclus
altern
rather
envisag
synergist
addon
canon
antiinfect
undoubtedli
futur
treatment
regimen
infecti
diseas
converg
concept
person
medicin
provid
best
possibl
combin
adjust
pathogen
also
patient
howev
clinic
benefit
socioeconom
effect
healthcar
system
would
impos
higher
cost
approach
remain
determin
moreov
hdt
adjunct
strategi
treatment
infect
infanc
requir
indepth
analysi
possibl
cytotox
potenti
worsen
infect
respect
hdt
also
requir
novel
think
side
drug
develop
side
legal
author
respons
approv
drug
nevertheless
given
progress
made
past
year
combin
canon
pathogendirect
novel
hostdirect
therapi
like
becom
indispens
